BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8522310)

  • 1. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
    Peralta Soler A; Knudsen KA; Jaurand MC; Johnson KR; Wheelock MJ; Klein-Szanto AJ; Salazar H
    Hum Pathol; 1995 Dec; 26(12):1363-9. PubMed ID: 8522310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
    Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
    Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: a ThinPrep immunocytochemical study.
    Han AC; Filstein MR; Hunt JV; Soler AP; Knudsen KA; Salazar H
    Cancer; 1999 Apr; 87(2):83-6. PubMed ID: 10227598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadherins, catenins and APC in pleural malignant mesothelioma.
    Abutaily AS; Collins JE; Roche WR
    J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Hum Pathol; 2003 Aug; 34(8):749-55. PubMed ID: 14506634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
    Abutaily AS; Addis BJ; Roche WR
    J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
    Müller AM; Weichert A; Müller KM
    Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas.
    Koukoulis GK; Shen J; Monson R; Warren WH; Virtanen I; Gould VE
    Hum Pathol; 1997 Jan; 28(1):84-90. PubMed ID: 9013837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of snail, twist, and Zeb1 in malignant mesothelioma.
    Merikallio H; Pääkkö P; Salmenkivi K; Kinnula V; Harju T; Soini Y
    APMIS; 2013 Jan; 121(1):1-10. PubMed ID: 23030626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
    Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.